CNS Pharmaceuticals, Inc.
CNSPNasdaq
$5.04
↑ +6.3%Jul 17 close · end-of-day
Price
1Y↓ -51.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.4M
Enterprise Value
$457,029.88
P/E
—
P/S
—
P/B
48.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$16.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-23317.0%
ROIC
—
Debt / Equity
—
Net Cash
$3.0M
Return 1Y
-53.1%
Company profile
CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.
- CEO
- John M. Climaco
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Texas
- Website
- cnspharma.com
Earnings
CNSP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$7.30↓ -61.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$16.0M |
| Net income | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Diluted EPS | — | -$16.50 | -$11.22 | -$12,509.11 | -$466.89 | -$35.75 |
| Operating cash flow | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Free cash flow | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$2.5M | -$5.6M | -$3.2M | -$4.3M | -$2.4M | -$3.3M | -$6.0M | -$5.0M |
| Net income | -$2.5M | -$5.6M | -$3.2M | -$4.3M | -$2.4M | -$3.2M | -$6.0M | -$4.9M |
| Diluted EPS | -$4,049.20 | -$153.20 | $4,755.99 | -$18.93 | -$6.42 | -$5.76 | -$4.64 | -$7.30 |
| Operating cash flow | -$1.7M | -$6.8M | -$5.5M | -$3.2M | -$5.3M | -$2.2M | -$3.1M | -$4.6M |
| Free cash flow | — | — | — | -$3.2M | — | — | — | -$4.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 14, 2026
May 4, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Charles Faith L. | Buy | 7,100 | $4.79 | $34,001.90 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.